Luca Grimaldi

Prof. Luca Grimaldi

Dept. of Med.Surg. Sciences, and Neurosciences, University of Siena, Siena, Tuscany, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
Andrea SistiAndrea Sisti
Andrea Sisti
LGLuca Grimaldi
Luca Grimaldi
JTJ. Tassinari
J. Tassinari
RCR. Cuomo
R. Cuomo
LFL. Fortezza
L. Fortezza
GNGiuseppe Nisi
Giuseppe Nisi

1 May 2001 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
CBCesare Brandi
Cesare Brandi
CDCarlo D'Aniello
Carlo D'Aniello
LGLuca Grimaldi
Luca Grimaldi
BBBruno Bosi
Bruno Bosi
IDIacopo Dei
Iacopo Dei
CACarlo Alessandrini
Carlo Alessandrini

1 October 2002 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
RPRoberto Petrioli
Roberto Petrioli
ACAndrea Coratti
Andrea Coratti
Pierpaolo CorrealePierpaolo Correale
Pierpaolo Correale
CDCarlo D’aNiello
Carlo D’aNiello
LGLuca Grimaldi
Luca Grimaldi
GFGuido Francini
Guido Francini
This randomized study compared the efficacy of epirubicin-based adjuvant chemotherapy on the disease-free interval (DFI) and overall survival of patients with high-risk soft-tissue sarcomas. After curative surgery, 43 of the 88 enrolled patients were assigned to surgery with or without radiotherapy and 45 to surgery plus chemotherapy (26 epirubicin, 19 epirubicin + ifosfamide) with or without radiotherapy. The trial closed prematurely because of poor patient accrual. There was a statistical significant difference in the 5-year disease-free survival of the patients receiving adjuvant chemotherapy with or without radiotherapy (69%) and that of those treated with surgery with or without radiotherapy (44%) (p = 0.01). The 5-year survival of the patients treated with adjuvant chemotherapy with or without radiotherapy was 72% as against 47% of those treated with surgery with or without radiotherapy (p = 0.06). The power of the study was 0.65 for both the DFI and overall survival. The results of the study suggest a possible advantage of epirubicin-based adjuvant chemotherapy in patients with soft-tissue sarcoma at high risk of relapse.

16 October 2016
Verified
Book Chapter
Closed access
PDF file
ROReuben Olaniyi
Reuben Olaniyi
CPClarissa Pozzi
Clarissa Pozzi
LGLuca Grimaldi
Luca Grimaldi
FBFabio Bagnoli
Fabio Bagnoli

1 August 2004 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
CBCesare Brandi
Cesare Brandi
CDCarlo D’aniello
Carlo D’aniello
LGLuca Grimaldi
Luca Grimaldi
ECElena Caiazzo
Elena Caiazzo
ESElisabetta Stanghellini
Elisabetta Stanghellini

1 June 2004 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
AAA Andreassi
A Andreassi
LGLuca Grimaldi
Luca Grimaldi
CDC D'Aniello
C D'Aniello
EPE Pianigiani
E Pianigiani
RBR Bilenchi
R Bilenchi
Ingrowing toenails are a common problem causing significant morbidity. Many of the procedures used for treating this painful condition cause considerable discomfort and have high failure rates. In recent years, phenol cauterization of the nail bed has been used increasingly. A retrospective study was carried out of all patients treated by this method in the authors' clinic during the period January 1996 to December 2001. In this study, phenol cauterization is the standard form of treatment and 948 phenol cauterizations were carried out in 764 patients. There was no significant morbidity and the procedure was tolerated well by all patients. Overall recurrence was 4.3% (33 patients) after 18 months. All symptomatic recurrences were successfully treated by repeating phenol cauterization. Phenol cauterization compares favourably with other surgical ablation techniques for ingrowing toenails and may be the ablation procedure of choice of an ingrowing toenail.